MannKind Corp (MNKD)
MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Co.'s primary product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Co. collaborates with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI.
MNKD SEC Filing Email Alerts Service
| Company Name: |
MannKind Corp |
| Website: |
www.mannkindcorp.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding MNKD: |
24 |
| Total Market Value Held by ETFs: |
$132.67M |
| Total Market Capitalization: |
$1.12B |
| % of Market Cap. Held by ETFs: |
11.79% |
|
|
April 25, 2024 • 11:52 PM Eastern
Strong Buy (3.67 out of 4)
65th percentile
|
|
Free MNKD Email Alerts:
